Xenon Pharmaceuticals Stock (NASDAQ: XENE)

Xenon Pharmaceuticals (NASDAQ:XENE) Stock, Quote.Headers.trade-ideas

Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.

laboratory-563423_1920

Analyst Color

Biotech

Equities

News

Health Care

Price Target

Initiation

Analyst Ratings

Trading Ideas

General

BHVN

CERE

KRTX

XENE

Biohaven&#39;s potential with RBC Capital Markets&#39; optimistic outlook.. RBC sees blockbuster potential of $3.2 billion across epilepsy and mood disorders. Anticipate significant developments in lead asset Kv7-7000&#39;s Phase 3 trial this year, reducing late-stage risks.

This Analyst Is Bullish On Biohaven&#39;s Approach in Neuro-Psych Space

Xenon Pharmaceuticals Inc (NASDAQ: XENE) shares are trading higher by 7.8% to $36.38 Thursday afternoon. The company announced the pricing of its upsized $300 million public offering of 8,461,542 common shares at 

Why Xenon Pharmaceuticals Stock (XENE) Is Seeing Blue Skies Today

Penny Stocks

Small Cap

Markets

AFRM

CHPT

CROX

LASR

SHOP

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Boeing To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Tuesday

Xenon Pharmaceuticals Inc. - Common Shares

Xenon Pharmaceuticals Inc

Xenetic Biosciences Inc

Xenetic Biosciences Inc Warrants (19/07/2024)

RBC Capital analyst Brian Abrahams reiterates Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Outperform and maintains $55 price target.

Reiteration

RBC Capital Reiterates Outperform on Xenon Pharmaceuticals, Maintains $55 Price Target

Xenon Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced the appointment of Matthew D. Ronsheim, Ph.D. as Chief Operating Officer and a member of the Xenon senior executive team. In this new role, Dr. Ronsheim will lead Chemistry, Manufacturing and Controls (CMC), Program Management and Quality Assurance and as a member of the senior executive team will be responsible for providing strategic and operational leadership for the Company's pipeline of small molecule programs with a focus on preparation for the commercial launch of azetukalner.

Management

Xenon Expands Leadership Team With Matthew D. Ronsheim as Chief Operating Officer

Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and lowers the price target from $62 to $60.

Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $60

Cantor Fitzgerald analyst Josh Schimmer reiterates Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Overweight and maintains $65 price target.

Cantor Fitzgerald Reiterates Overweight on Xenon Pharmaceuticals, Maintains $65 Price Target

Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Outperform and lowers the price target from $50 to $49.

Wedbush Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $49

Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.70) by 7.14 percent.

Earnings

Earnings Misses

Xenon Pharmaceuticals Q2 2024 GAAP EPS $(0.75) Misses $(0.70) Estimate

Events

Xenon Pharmaceuticals Presents Phase 2 X-NOVA Clinical Trial Data Of Azetukalner in Major Depressive Disorder At ASCP 2024 Annual Meeting

Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and maintains $62 price target.

Needham Maintains Buy on Xenon Pharmaceuticals, Maintains $62 Price Target

Citigroup analyst David Hoang maintains Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and lowers the price target from $62 to $60.

Citigroup Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $60

Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Outperform and lowers the price target from $51 to $50.

Wedbush Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $50

Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.66) by 6.06 percent.

Earnings Beats

Xenon Pharmaceuticals Q1 2024 Adj EPS $(0.62) Beats $(0.66) Estimate

Xenon's Oral Presentations at AAN
Oral Presentation #005 (French et al.) "Interim, Long-term, Safety and Efficacy of XEN1101, a Potent, Selective Potassium Channel Opener: Update from an Ongoing Open-label Extension of a Phase 2b Study (X-TOLE) in Adults with Focal Epilepsy." Session 19: Epilepsy Clinical Trials and Long-term Studies Oral Presentation #004 (Porter et al.) "The Impact of Disease Severity on Responder Rates in a Phase 2b Study of XEN1101, a Potent, Selective Potassium Channel Opener, in Adults With Focal Epilepsy (X-TOLE)." Session 19: Epilepsy Clinical Trials and Long-term Studies
Xenon is also hosting Booth #1797 in the AAN Exhibit Hall, which runs until Wednesday, April 17, 2024 at 4:00 pm MT.

Xenon Pharmaceuticals Announced Two Oral Presentations For XEN1101 Clinical Data At AAN 2024 Annual Meeting

Needham analyst Serge Belanger reiterates Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and maintains $62 price target.

Needham Reiterates Buy on Xenon Pharmaceuticals, Maintains $62 Price Target

RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Outperform and lowers the price target from $56 to $55.

RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $55

Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Outperform and raises the price target from $46 to $51.

Wedbush Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $51

Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and raises the price target from $50 to $62.

Needham Maintains Buy on Xenon Pharmaceuticals, Raises Price Target to $62

Guidance

Xenon Pharmaceuticals Anticipates Having Sufficient Cash To Fund Operations Into 2027

Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.76) by 15.79 percent. This is a 12.28 percent decrease over losses of $(0.57) per share from the same period last year.

Xenon Pharmaceuticals Q4 EPS $(0.64) Beats $(0.76) Estimate

Needham analyst Serge Belanger maintained a Buy rating on Xenon (XENE – Research Report) today and set a price target of $60.00. Serge Belanger has...

Buy Rating Affirmed for Xenon Amid Progress in Key Pharmaceutical Trials and Strong Financial Standing

Xenon Pharmaceuticals, Inc. (XENE) Q2 2024 Earnings Call Transcript

Xenon Pharma files for automatic mixed securities shelf

Xenon Pharmaceuticals: Good Data In Epilepsy, But Doubts Remain

Xenon names Matthew Ronsheim as chief operating officer

Xenon (XENE) has released an update. Xenon Pharmaceuticals Inc. has strengthened its leadership team by appointing Matthew D. Ronsheim, Ph.D. as th...

Xenon Pharmaceuticals Appoints New COO

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Xenon (XENE – Research Report), Nuvalent (NUVL – Res...

Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Nuvalent (NUVL) and Dianthus Therapeutics (DNTH)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Crinetics Pharmaceuticals (CRNX – Research Report), ...

Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Prothena (PRTA) and Xenon (XENE)

RBC Capital analyst Brian Abrahams maintained a Buy rating on Xenon (XENE – Research Report) today and set a price target of $55.00. The company's ...

RBC Capital Sticks to Its Buy Rating for Xenon (XENE)

Xenon (XENE) has released an update. Xenon Pharmaceuticals Inc. presented compelling long-term data and reported quality of life improvements for a...

Xenon's Azetukalner Marks Success in Epilepsy Treatment

CRNX

DNTH

GLAXF

NBIX

NUVL

PRTA

Press Releases

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update

Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference

Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024

Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Xenon Pharmaceuticals

Xenon Pharmaceuticals (XENE) Forecast

Xenon Pharmaceuticals (NASDAQ:XENE) Stock, Quote.Headers.trade-ideas